Keybank National Association OH decreased its position in shares of GRIFOLS S A/S (NASDAQ:GRFS) by 4.7% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 40,355 shares of the biotechnology company’s stock after selling 1,985 shares during the period. Keybank National Association OH’s holdings in GRIFOLS S A/S were worth $809,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Thomas White International Ltd. acquired a new stake in shares of GRIFOLS S A/S in the second quarter worth about $84,000. Assetmark Inc. lifted its position in shares of GRIFOLS S A/S by 453.8% in the second quarter. Assetmark Inc. now owns 6,363 shares of the biotechnology company’s stock worth $134,000 after buying an additional 5,214 shares during the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lifted its position in shares of GRIFOLS S A/S by 24.2% in the second quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 7,818 shares of the biotechnology company’s stock worth $165,000 after buying an additional 1,522 shares during the last quarter. First Light Asset Management LLC acquired a new stake in shares of GRIFOLS S A/S in the second quarter worth about $215,000. Finally, Blackhawk Capital Partners LLC. acquired a new stake in shares of GRIFOLS S A/S in the second quarter worth about $254,000. 17.67% of the stock is owned by hedge funds and other institutional investors.
Shares of GRIFOLS S A/S stock traded up $0.56 during trading on Wednesday, reaching $21.93. The company’s stock had a trading volume of 45,813 shares, compared to its average volume of 1,165,786. The company has a debt-to-equity ratio of 1.30, a quick ratio of 0.96 and a current ratio of 2.62. The business’s fifty day moving average price is $20.76 and its 200-day moving average price is $20.48. The firm has a market cap of $14.80 billion, a price-to-earnings ratio of 18.68, a price-to-earnings-growth ratio of 1.37 and a beta of 1.08. GRIFOLS S A/S has a one year low of $17.42 and a one year high of $23.03.
About GRIFOLS S A/S
Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes a range of biological medicines on plasma derived proteins worldwide. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use; and sells and distributes end products.
Read More: What is Green Investing?
Want to see what other hedge funds are holding GRFS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GRIFOLS S A/S (NASDAQ:GRFS).
Receive News & Ratings for GRIFOLS S A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRIFOLS S A/S and related companies with MarketBeat.com's FREE daily email newsletter.